Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis

Narciso-Schiavon, Janaína Luz; Pereira, Jéssica G.; Silva, Telma Erotides; Bansho, Emilia Tiemi Oshiro; Morato, Edelton Flávio; Pinheiro, José T.; Muraro-Wildner, Letícia; Bazzo, Maria Luiza; Dantas-Corrêa, Esther Buzaglo; Schiavon, Leonardo Lucca

doi:10.5604/01.3001.0010.2789

Cited by 18 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean MELD score in that study was nearly twofold higher than of the patients enrolled in the present investigation. Indeed, patients with a MELD score over 20 had higher systemic PTX3 than patients with a lower score [21]. However, similar to our findings, PTX3 levels were not different in Child-Pugh class A, B, and C patients [21].…”

Section: Discussionsupporting

confidence: 87%

“…Indeed, patients with a MELD score over 20 had higher systemic PTX3 than patients with a lower score [21]. However, similar to our findings, PTX3 levels were not different in Child-Pugh class A, B, and C patients [21]. Hence, PTX3 is not associated with the severity of liver disease.…”

Section: Discussionsupporting

confidence: 83%

“…Several pro-and anticoagulant factors are produced in the liver, and consequently, both pathways are impaired in patients with liver cirrhosis [40]. PTX3 was higher in cirrhotic patients than controls, whereas prothrombin conversion as well as thrombin inactivation was impaired in these patients [21,40]. This suggests that raised PTX3 in liver cirrhosis may in part compensate for deficiencies in proas well as anticoagulatory pathways.…”

Section: Discussionmentioning

confidence: 99%

“…Hence, PTX3 is not associated with the severity of liver disease. High levels are more likely related to severe complications such as acute-on-chronic liver failure or infections [21].…”

Section: Discussionmentioning

confidence: 99%

“…The prevailing opinion nowadays is that systemic PTX3 is induced in patients with chronic liver diseases [11,19] and has a positive predictive value for adverse clinical outcomes [20,21]. Liver cirrhosis is a risk factor for HCC, and PTX3 may also have a role herein [17,22].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

et al. 2020

View full text Add to dashboard Cite

The acute-phase protein pentraxin-3 (PTX3) is a component of the innate immune system. Inflammation and tissue injury increased PTX3 in the injured liver, and accordingly, circulating PTX3 was induced in patients with chronic liver diseases. In the present study, PTX3 protein was determined in systemic, hepatic, and portal vein plasma of patients with liver cirrhosis to assess a possible association between hepatic PTX3 release and extent of liver injury. However, PTX3 levels were not related to disease severity. Of note, portal PTX3 levels were higher than concentrations in the hepatic vein. PTX3 in the hepatic and portal veins was negatively correlated with factor V, antithrombin 3, and prothrombin time. PTX3 did neither correlate with C-reactive protein nor galectin-3 or resistin, whereby the latter two proteins are associated with hepatic injury. PTX3 levels were not changed in cirrhosis patients with ascites or varices and did not correlate with the hepatic venous pressure gradient. Likewise, serum PTX3 was not correlated with histological steatosis, inflammation, or fibrosis stage in patients with hepatocellular carcinoma (HCC). Moreover, PTX3 was not associated with tumor node metastasis classification in HCC. Above all, PTX3 increased in hepatic, portal, and systemic blood immediately after transjugular intrahepatic portosystemic shunt (TIPS). Higher PTX3 in portal than hepatic vein plasma and further increase after TIPS suggests that the liver eliminates PTX3 from the circulation. In summary, PTX3 is not of diagnostic value in cirrhosis and HCC patients.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

“…Hence, PTX3 is not associated with the severity of liver disease. High levels are more likely related to severe complications such as acute-on-chronic liver failure or infections [21].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

et al. 2020

View full text Add to dashboard Cite

show abstract

Per‐ and polyfluoroalkyl substances activate UPR pathway, induce steatosis and fibrosis in liver cells

Niture

Gadi

et al. 2022

Environmental Toxicology

View full text Add to dashboard Cite

Per-and polyfluoroalkyl substances (PFAS), which include perfluorooctanoic acid (PFOA), heptafluorobutyric acid (HFBA), and perfluorotetradecanoic acid (PFTA), are commonly occurring organic pollutants. Exposure to PFAS affects the immune system, thyroid and kidney function, lipid metabolism, and insulin signaling and is also involved in the development of fatty liver disease and cancer. The molecular mechanisms by which PFAS cause fatty liver disease are not understood in detail. In the current study, we investigated the effect of low physiologically relevant concentrations of PFOA, HFBA, and PFTA on cell survival, steatosis, and fibrogenic signaling in liver cell models. Exposure of PFOA and HFBA (10 to 1000 nM) specifically promoted cell survival in HepaRG and HepG2 cells. PFAS increased the expression of TNFα and IL6 inflammatory markers, increased endogenous reactive oxygen species (ROS) production, and activated unfolded protein response (UPR). Furthermore, PFAS enhanced cell steatosis and fibrosis in HepaRG and HepG2 cells which were accompanied by upregulation of steatosis (SCD1, ACC, SRBP1, and FASN), and fibrosis (TIMP2, p21, TGFβ) biomarkers expression, respectively. RNA-seq data suggested that chronic exposures to PFOA modulated the expression of fatty acid/lipid metabolic genes that

show abstract

Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?

et al. 2021

View full text Add to dashboard Cite

Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis

Abstract: These results indicate the potential for use of PTX3 as an inflammatory biomarker for the prognosis of patients with hepatic cirrhosis.

Cited by 18 publications

References 31 publications

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

Pentraxin-3 is not related to disease severity in cirrhosis and hepatocellular carcinoma patients

Per‐ and polyfluoroalkyl substances activate UPR pathway, induce steatosis and fibrosis in liver cells

Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma?

Contact Info

Product

Resources

About